phosphamide and cimetidine but we have been unable to obtain any potentiation with this combination using the Walker carcinoma. A direct anti-tumour effect of cimetidine has also been reported (Gifford et al., 1981; Osband et al., 1981) , though again such an effect could not be demonstrated in the present studies.
Although the relationship of H2-receptor antagonism to anti-tumour activity is unclear, H2-receptor antagonists have other activities, such as the inhibition of the microsomal P450 system by cimetidine (Pelkonen & Puurunen, 1980) , which suggest that they would influence the metabolism of other drugs and this indeed has been shown to be the case (Serlin et al., 1979; Desmond et al., 1980a, b) . It is also believed that cimetidine interferes with suppressor-cell function (Daman & Rosenberg, 1977; Jorizzo et al., 1980) , and that this action is responsible for its direct anti-tumour effect (Osband et al., 1981) .
The purpose of the present study was to enlarge on the initial findings of enhancement of razoxane anti-tumour activity in cimetidine-pretreated animals by examining this effect with a wider spectrum of tumours, a larger number of anti-tumour agents and structural analogues of H2-receptor antagonists.
Six-week old female Sprague-Dawley rats weighing 200 g were used in all experiments. Walker tumour mash (0 3 ml) was injected s.c. on Day 0 and animals were dosed on Days 1, 2, 3 and 4. The end-point of reduction of tumour weight on Day 8 was used to assess the anti-tumour effect of chemotherapeutic agents. All drugs were given orally and H2-receptor antagonists given 1 h before administration of anti-cancer agents.
Sarcoma 180 tumour mash (0-1 ml) was injected s.c. into the flanks of male Schneider mice on Day 0. Animals were dosed with razoxane at 2-5 mg/kg on Days 1, 2, 3, 6 and 7 and reduction of tumour weight used to assess antitumour effect.
L1210 cell suspension (5 x 105 cells in 041 ml) was injected s.c. into the flanks of male BDF mice on Day 0. Animals were dosed with razoxane 50, 100, 150, 200 or 250 mg/kg on Day 2 and increase in life-span used to assess anti-tumour effect.
Lewis lung carcinoma tumour mash (0.1 ml) was injected s.c. into the flanks of C57B1 female mice on Day 0. Animals were dosed with razoxane 75 or 100 mg/kg on Day 3 and reduction of Day 21 tumour weight was used to assess chemotherapeutic response. TLX5 cell suspension (2 x 106 cells in 0-1 ml) was injected s.c. into the flanks of female CBA mice. Animals were dosed with razoxane 150 mg/kg on Day 3 and increase in life-span used to assess antitumour activity.
All drugs were given orally and cimetidine given 1 h before administration of razoxane except where stated.
Cimetidine Rats pretreated with cimetidine demonstrated a significantly greater anti-tumour effect in response to the anti-tumour agent razoxane than rats not pretreated with cimetidine (Fig. 1) . Cimetidine alone possessed no anti-tumour activity even at doses up to 400 mg/kg, nor were any visible signs of toxicity noted up to this dose level either alone or in combination with the anti-cancer agent.
The enhancement of anti-tumour activity occurred with the active H2-receptor antagonists metiamide, which is a structural analogue of cimetidine, and also with ranitidine, another type of H2-receptor antagonist (Fig. 1) . Again, no anti-tumour activity was seen with H2-receptor antagonists alone. No enhancement was obtained by pretreatment with structural analogues SKF 91581 and AH 19659, which are devoid of H2-antagonist activity (Fig. 1) . No antitumour activity was seen with these inactive analogues alone. A link between H2-receptor antagonism and anti-tumour drug activity was suggested by Collins (1980 Collins ( , 1981 and there is some evidence to support this theory. Firstly there was the chance observation by Armitage & Sidner (1979) Early studies with H2-receptor antagonists revealed no significant interactions with other compounds (Lesley & Walker, 1977) , but a number of reports have now appeared suggesting that the H2-receptor antagonist, cimetidine, significantly interferes with the action of other drugs. These include the anticoagulants (Serlin et al., 1979) , the methylxanthines (Desmond et al., 1980b) , minor tranquillizers (Desmond et al., 1980a; Klotz et al., 1979) and the barbiturates (Pelkonen & Puurunen, 1980; Dorr & Alberts, 1982) .
Although the mechanism of H2-receptor involvement in anti-tumour drug activity remains obscure, Gifford et al. (1981) and Osband et al. (1981) have suggested inhibition of suppressor-cell function by cimetidine, while Dorr & Alberts (1982) explain their results through an interference with the microsomal metabolism of compounds utilizing the P450 system as previously suggested by Pelkonen & Puurunen (1979 , 1980 , or via a change in liver blood flow as demonstrated for cimetidine by Feely et al. (1981) .
Both Gifford et al. (1981) and Osband et al. (1981) demonstrated a direct antitumour effect of cimetidine in vivo reflected by prolonged survival of tumourbearing animals and a slowing of metastatic development. However, we have been unable to detect any direct anti-tumour effect of cimetidine in the Walker tumour or against any mouse tumour. We have also been unable to demonstrate a direct cytotoxic effect of cimetidine against L1210 cells in vitro which was in agreement with the in vitro results of Gifford et al. (1981) using EL4 cells.
Our results show a significant enhancement by cimetidine of the anti-tumour activity of only 1 anti-cancer agent, razoxane. This enhancement was specific to active H2-receptor antagonists, and structural analogues having no such antagonist activity were devoid of this effect. Thus H2-antagonism appears to be a prerequisite for enhancement of anti-tumour activity in these experiments.
However, unlike Dorr & Alberts (1982) , we were unable to demonstrate any enhancement of cyclophosphamide antitumour activity by cimetidine, and this discrepancy may be attributed to the use of a different tumour system, or the fact that Dorr & Alberts administered the drug i.p. directly to the site of the tumour. In our experiments both drugs were administered by the more therapeutically relevant oral route. We were also unable to demonstrate any enhancement of the anti-tumour activity of methotrexate or 5-fluorouracil.
Whilst cimetidine has been reported to reduce the oxidative metabolism of many drugs by inhibition of the P450 enzyme system, ranitidine has no such activity (Henry et al., 1980) . It therefore seems unlikely that the H2-antagonistpotentiating effect of the anti-tumour action of razoxane is mediated through this mechanism. However, cimetidine has been reported to reduce liver blood flow (Feely et al., 1981) and it could therefore be that it might have an effect on tumour blood vessels. Since it had earlier been shown that razoxane normalizes the development of the tumour neovasculature (Le Serve & Hellmann, 1972) it may be possible that the 2 drugs interact at this level.
In conclusion, we have demonstrated an interaction between several H2-receptor antagonists and at least one anti-cancer agent, leading to enhancement of anticancer activity of this agent by an as yet unknown mechanism. The H2-antagonists demonstrated no direct anti-tumour activity either in vivo or in vitro. The interaction between H2-receptor antagonists was specific to activate antagonists and did not occur with analogues devoid of antagonist activity.
